Topics include:

• FDA-approved targeted therapies for patients with cholangiocarcinoma 
• Mechanism of action of FGFR inhibitors and review of the efficacy and safety data from pivotal trials 
• Physician experience with managing common adverse events associated with FGFR inhibitors 
• Considerations for the place of FGFR inhibitors in line of therapy, including discussion of new agents currently in development 

Featuring:

Milind Javle, MD

Hubert L. and Olive Stringer Professor, Gastrointestinal Medical Oncology
Attending Physician, Program Lead, Biliary Cancer Program
The University of Texas MD Anderson Cancer Center
Houston, TX
Director, The Cholangiocarcinoma Foundation International
Cholangiocarcinoma Research Network
Salt Lake City, UT
Chair, NCI Task Force Hepatobiliary Cancers

Amit Mahipal, MBBS, MPH

Director, Gastrointestinal Oncology, University Hospitals, Seidman Cancer Center
Professor, Medicine, Case Western Reserve University
Cleveland, OH